A possibility worth worth contemplating, page-10

POS, Perhaps a tad simplistic with ACL. Not championing management there by any means, but their drug's efficacy may have had something to do with the fall from grace. Promising Phase 2, followed by a shock bomb out of a Phase 3. The best management in the universe can not command a drug's efficacy. Trofinetide, although promising, is still in the early stages of demonstrating efficacy and there are a few hurdles to jump yet. I am happy to back it all the way, but I think that ACL is a salutary reminder of the risks yet to be put to bed. I would much prefer to keep my excitement levels not too far ahead of what has actually been achieved to date in the full realisation that there are many potential precipices to be navigated in biotech drug development stories.